Research
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
-
* Corresponding author: Richard Beale Richard.Beale@gstt.nhs.uk
1 Division of Pulmonary, Allergy, and Critical Care, Emory University, 615 Michael Street, Atlanta, Georgia, 30322, USA
2 Department of Anesthesiology and Intensive Care, Friedrich Schiller University, Erlanger Allee 101, Jena, 07743, Germany
3 Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana, 46285, USA
4 i3 StatProbe, 1001 Winstead Drive, Cary, North Carolina, 27513, USA
5 Intensive Care Unit, Guy's and St Thomas' Hospital, Lambeth Palace Road, London, SE1 7EH, UK
Critical Care 2009, 13:R103 doi:10.1186/cc7936
Published: 30 June 2009Additional files
Additional file 1:
A word file containing a more detailed methodology of the propensity model development and a table (Table S1 in Additional data file 1) demonstrating the balance among baseline characteristics between the two treatment groups achieved in the propensity quartiles.
Format: DOCX Size: 26KB Download file
